China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval

By Reuters News

** Shares of HUTCHMED (China) 0013.HK climb 4.1% to HK$23.1, their highest level since September 4

** Stock on track for its biggest one-day pct gain since September 21

** HUTCHMED said on Tuesday that Anglo-Swedish drugmaker AstraZeneca AZN.L had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer

** ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca

** YTD, HUTCHMED's Hong Kong stock up 11%, Hang Seng Biotech Index .HSBIO up 14%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.